There are currently 110 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT05867251
Recruiting
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: Yale Cancer Center, New Haven, Connecticut +9 locations
Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Register for Updates
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT05520099
Recruiting
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform across a basket of solid tumors, using in-vivo RECIST 1.1 as the reference method.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Salinas Valley Memorial Healthcare System, Salinas, California +10 locations
Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Endometrial Cancer, Colorectal Cancer, Cutaneous Melanoma, Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Register for Updates
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT05691010
Recruiting
The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey +6 locations
Conditions: Endometrial Cancer, Stage III Endometrial Cancer, Stage III Endometrial Carcinoma, Endometrial Carcinoma, Endometrial Carcinoma Stage III
Register for Updates
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112
Recruiting
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Research Site, Tucson, Arizona +210 locations
Conditions: Endometrial Cancer
Register for Updates
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264
Recruiting
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Hoag Memorial Presbyterian, Newport Beach, California +32 locations
Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Register for Updates
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692
Recruiting
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Sharp Memorial Hospital, San Diego, California +23 locations
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, Colorectal Cancer (MSI-H), MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Register for Updates
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521
Recruiting
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/14/2025
Locations: START Midwest, Grand Rapids, Michigan +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, NUT Carcinoma
Register for Updates
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
Recruiting
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +8 locations
Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Register for Updates
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
NCT04291612
Recruiting
This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a lymphedema.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut +18 locations
Conditions: Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
Register for Updates
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT04569773
Recruiting
The purpose of this study is to learn more about the factors that influence decision-making before surgery (distress about cancer and/or reproductive concerns) and the possibility of regret after surgery.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/13/2025
Locations: Hartford Healthcare (Data Collection), Hartford, Connecticut +7 locations
Conditions: Endometrial Cancer
Register for Updates
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
NCT05761951
Recruiting
To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776
Recruiting
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia +59 locations
Conditions: Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Register for Updates